Literature DB >> 31971601

Psoriasis and Treatment: Past, Present and Future Aspects.

Claire Reid1, Christopher E M Griffiths.   

Abstract

The management of psoriasis has evolved considerably over the past 100 years. This has occurred in parallel with our understanding of the pathogenesis of this common, complex and enigmatic disease. It should be celebrated as an outstanding example of successful translational research. With precise targeting of immune pathways for the treatment of psoriasis with new biologics and small molecules has come the realisation that the most effective approach to patient management is a holistic one which encompasses the biopsychosocial nature of the disease. This involves a stratified medicine approach to identifying the best drug for an individual allied to patient education, screening for comorbidity, and regular review as both the clinical presentation and the patient's needs will change over time. Al-though there is not yet a cure for psoriasis - the whole person, systems approach to patient management, that is in part dependent on early intervention, should help to ensure an optimal outcome.

Entities:  

Keywords:  psoriasis; treatment

Mesh:

Substances:

Year:  2020        PMID: 31971601      PMCID: PMC9128930          DOI: 10.2340/00015555-3386

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  101 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  The effect of topically applied compound F in selected dermatoses.

Authors:  M B SULZBERGER; V H WITTEN
Journal:  J Invest Dermatol       Date:  1952-08       Impact factor: 8.551

3.  British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018.

Authors:  J Berth-Jones; L S Exton; E Ladoyanni; M F Mohd Mustapa; V M Tebbs; P D Yesudian; N J Levell
Journal:  Br J Dermatol       Date:  2019-04-07       Impact factor: 9.302

4.  British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.

Authors:  R B Warren; S C Weatherhead; C H Smith; L S Exton; M F Mohd Mustapa; B Kirby; P D Yesudian
Journal:  Br J Dermatol       Date:  2016-07       Impact factor: 9.302

5.  Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.

Authors:  J A Parrish; T B Fitzpatrick; L Tanenbaum; M A Pathak
Journal:  N Engl J Med       Date:  1974-12-05       Impact factor: 91.245

6.  An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Richard B Warren; Ulrich Mrowietz; Ralph von Kiedrowski; Johannes Niesmann; Dagmar Wilsmann-Theis; Kamran Ghoreschi; Ina Zschocke; Thomas M Falk; Norbert Blödorn-Schlicht; Kristian Reich
Journal:  Lancet       Date:  2016-12-22       Impact factor: 79.321

7.  Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.

Authors:  Kristian Reich; April W Armstrong; Richard G Langley; Susan Flavin; Bruce Randazzo; Shu Li; Ming-Chun Hsu; Patrick Branigan; Andrew Blauvelt
Journal:  Lancet       Date:  2019-08-08       Impact factor: 79.321

8.  Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas.

Authors:  J P Ortonne; P Humbert; J F Nicolas; N Tsankov; S D Tonev; A Janin; J Czernielewski; M Lahfa; L Dubertret
Journal:  Br J Dermatol       Date:  2003-02       Impact factor: 9.302

Review 9.  Methotrexate for psoriasis in the era of biological therapy.

Authors:  R B Warren; R J G Chalmers; C E M Griffiths; A Menter
Journal:  Clin Exp Dermatol       Date:  2008-08       Impact factor: 3.470

Review 10.  Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.

Authors:  Melinda Gooderham; Kim Papp
Journal:  BioDrugs       Date:  2015-10       Impact factor: 5.807

View more
  12 in total

1.  Remodeling of the Dermal Extracellular Matrix in a Tissue-Engineered Psoriatic Skin Model by n-3 Polyunsaturated Fatty Acids.

Authors:  Mélissa Simard; Alexe Grenier; Geneviève Rioux; Andréa Tremblay; Isalie Blais; Nicolas Flamand; Roxane Pouliot
Journal:  Biomedicines       Date:  2022-05-06

2.  Longitudinal Changes in Skin Microbiome Associated with Change in Skin Status in Patients with Psoriasis.

Authors:  Hailun Wang; Mandy W M Chan; Henry H Chan; Herbert Pang
Journal:  Acta Derm Venereol       Date:  2020-11-24       Impact factor: 3.875

3.  The Diagnostic-Therapeutic Care Pathway in Psoriasis: Towards ISO 9001:2015 Certification.

Authors:  Federica Veronese; Francesca Graziola; Edoardo Cammarata; Marco Andreassi; Vanessa Mazzoletti; Camilla Taglietti; Gaia Navarra; Paola Savoia; Rossana Tiberio
Journal:  Medicina (Kaunas)       Date:  2020-05-22       Impact factor: 2.430

4.  Evaluation of the relationship of IL-17A and IL-17F gene polymorphisms with the response to treatment in psoriatic patients using biological drugs: a case-control study in patients in Eastern Turkey.

Authors:  Hatice Uce Ozkol; Gokhan Gorgisen; Can Ates; Halil Özkol; Yasin Tülüce; Hulya Savas; İsmail Musab Gulacar
Journal:  Postepy Dermatol Alergol       Date:  2020-05-26       Impact factor: 1.837

5.  Dual specificity phosphatase 22 relates to skin lesion degree and biologics history, while its longitudinal elevation during treatment reflects better outcome in psoriasis patients.

Authors:  Cailing E; Yong Fang; Shixing Wu; Zudong Meng; Guifang Qin; Jiaoli Yang
Journal:  J Clin Lab Anal       Date:  2021-12-31       Impact factor: 2.352

Review 6.  What Can IBD Specialists Learn from IL-23 Trials in Dermatology?

Authors:  Mario Valenti; Alessandra Narcisi; Giulia Pavia; Luigi Gargiulo; Antonio Costanzo
Journal:  J Crohns Colitis       Date:  2022-05-11       Impact factor: 10.020

7.  The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics

Authors:  Imke Nordhorn; Daniela Weiss; Thomas Werfel; Alexander Zink; Maximilian C Schielein; Stephan Traidl
Journal:  Eur J Dermatol       Date:  2022-04-01       Impact factor: 2.805

8.  Curcumin and Curcuma longa Extract in the Treatment of 10 Types of Autoimmune Diseases: A Systematic Review and Meta-Analysis of 31 Randomized Controlled Trials.

Authors:  Liuting Zeng; Tiejun Yang; Kailin Yang; Ganpeng Yu; Jun Li; Wang Xiang; Hua Chen
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

9.  Erianin-Loaded Photo-Responsive Dendrimer Mesoporous Silica Nanoparticles: Exploration of a Psoriasis Treatment Method.

Authors:  Huanan Yu; Yuanqi Liu; Fang Zheng; Wenyu Chen; Kun Wei
Journal:  Molecules       Date:  2022-09-26       Impact factor: 4.927

10.  Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis.

Authors:  Martin Bauer; Edith Lackner; Peter Matzneller; Valentin Al Jalali; Sahra Pajenda; Vincent Ling; Christof Böhler; Werner Braun; Reinhard Braun; Maximilian Boesch; Patrick M Brunner; Markus Zeitlinger
Journal:  Front Med (Lausanne)       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.